entertainment -WSS

entertainment

author：leisure time 2025-10-02 10:45:33 - browse：88458

Three boxes of Wegovy stands in a line — coverage from STAT — Steffen Trumpf/picture alliance/Getty Images

LONDON — Starting in the new year, a team of researchers in the U.K. and Denmark will begin recruiting patients for a study driven by a pressing question in medicine: How should new obesity medications be incorporated into regular practice?

Trials have demonstrated that the powerful drugs can help people shed weight in dramatic ways, but clinicians are still trying to sort out how to best use them. The medicines, after all, are pricey, come with side effects, and won’t work for everyone. And despite the excitement around these drugs, known as GLP-1s, some people might prefer or see better results with the other approaches that have long been the foundation of obesity treatment, from diet to surgery.

“These drugs clearly are very effective, and that is fantastic,” said Susan Jebb, a professor of diet and population health at the University of Oxford and one of the leaders of the project. “But we have other options for treating obesity. What we need to do now in research is understand which treatments, for which patients, at which stage of their disease.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Intercept Pharmaceuticals sells itself for less than $1 billion

focus

WSS

Shingles, which affected Dianne Feinstein, is on the rise

Southern California school board OKs curriculum after Gov. Gavin Newsom threatened a $1.5M fine

Sudafed saga points to U.S. issues with evaluating older drugs

Biogen shutters digital health group, ends Apple study, in cost cutting move

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

AbbVie dramatically boosts its spending on lobbying

entertainment

entertainment

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Address the ethical violations that led to 'Three Identical Strangers'

Drug repurposing or repositioning? The language matters

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Medicare details structure of new drug price negotiation program

Kaiser Permanente unions announce official strike date

Bright Health sells Medicare Advantage business to Molina

Listen: Who gets the credit for GLP

Duchenne breakthrough therapy leaves behind pioneering families

HIPAA doesn't protect reproductive records from prosecutors

entertainment

Menendez indictment could see pharma lose a key ally

Mindstrong's demise and the future of mental health care

FDA official pushes for dedicated emerging pathogens team

Mindstrong's demise and the future of mental health care

Artificial intelligence advances fuel industry trying to preserve loved ones after death

WHO recommends dropping component of many flu vaccines

focus

entertainment

focus

hotspot